Stock Code: 000999 Stock Abbreviation: China Resources Sanjiu Announcement No.: 2026-009
China Resources Sanjiu Pharmaceutical Co., Ltd.
Progress Announcement on the "Dual Improvement of Quality and Returns" Action Plan
The company and all members of the board of directors guarantee that the content of the information disclosure is true, accurate, and complete, with no false records, misleading statements, or major omissions.
In order to implement the investor-centered development philosophy, China Resources Sanjiu Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu" or "the Company") attaches great importance to the disclosure of the "Announcement on the 'Dual Improvement of Quality and Returns' Action Plan" on March 9, 2024 (Announcement No.: 2024-022).
According to the content of the "Dual Improvement of Quality and Returns" action plan, the Company actively carries out and implements relevant work. The relevant situation for the year 2025 is as follows:
I. Focus on Core Business Development, Strive to Become an Industry Leader
The Company's vision is "to become a leader in the public pharmaceutical health industry," innovatively applying both traditional Chinese and Western medical science and technology, focusing on high-quality pharmaceutical health product innovation and intelligent manufacturing, serving every member of Chinese families, and striving to become the number one brand in China's pharmaceutical health sector.
Since the 14th Five-Year Plan, China Resources Sanjiu has adhered to the mission of "Caring for Public Health, Creating a Better Life," examining and predicting changes, focusing on development needs, and deeply promoting the execution of the "14th Five-Year" strategic plan. China Resources Sanjiu actively adapts and confronts challenges, insisting on the dual-driven approach of "Innovation + Brand," steadily advancing in line with strategic direction, and successfully achieving the strategic goal of "doubling operating income." In 2025, the Company achieved operating income of 31.603 billion yuan, a year-on-year increase of 14.43%; the net profit attributable to shareholders of the listed company was 3.421 billion yuan, a year-on-year increase of 1.58%.
(1) Brand Influence Continues to Deepen, Brand Leadership Position Consolidated
The Company focuses on the "1+N" brand strategy, building on the "999" family staple brand, and has successively developed well-recognized pharmaceutical brands such as "Tianhe," "Shunfeng," "Aonuo," and "Kunzhongyao 1381." The Company continues to explore innovative communication paths with consumers, implementing cross-platform and multi-faceted brand interactions and innovative marketing activities, injecting fresh elements into the brand and revitalizing its youthful energy, while continuously consolidating its industry-leading position in categories such as respiratory, skin, and cardiovascular health. The Company has ranked first in the comprehensive ranking of non-prescription drug manufacturers published by the China Non-Prescription Drug Association for several consecutive years.